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Abstract
Objective: To evaluate the prices and availability of paediatric essential medicines in Shaanxi Province, China.
Methods: Price and availability data for 28 paediatric essential medicines were collected from 60 public hospitals and 60
retail pharmacies in six areas of Shaanxi Province using a standardised methodology developed by the World Health
Organization and Health Action International, during November to December 2012. Affordability was measured as the
number of days’ wages required for the lowest-paid unskilled government worker to purchase standard treatments for
common conditions. Data on medicine price components were collected from hospitals, wholesalers and distributors to
obtain price mark-ups.
Findings: The mean availabilities of originator brands (OBs) and lowest-priced generics (LPGs) were 10.8% and 27.3% in the
public hospitals and 11.9% and 20.6% in the private pharmacies. The public procurement and retail prices were 2.25 and
2.59 times the international reference prices (IRPs) for three OBs, and 0.52 and 0.93 times for 20 LPGs. In the private sector,
the final prices for OBs and LPGs were 3.89 and 1.25 times their IRPs. The final price in the private sector was 2.7% lower
than in the public sector for OBs, and 14.1% higher for LPGs. Generally, standard treatments cost less than 1 day’s wages in
both sectors. Distribution mark-ups applied to brand salbutamol in Xi’an was 65.5%, and up to 185.3% for generic.
Cumulative mark-ups for LPGs in Ankang were also high, from 33% to 50%. The manufacturer’s selling price is the largest
contributor to the final price in both areas.
Conclusions: The government should approve a list of national paediatric essential medicines. The availability, price and
affordability of these should be improved in both public hospitals and private pharmacies to enable children to obtain
effective treatment. Measures should be taken to improve the efficiency of the centralised medicine purchasing system.
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Introduction
According to the World Health Organization (WHO), 6.6
million children under the age of five years died in 2012. The
leading causes of death were pneumonia, preterm birth compli-
cations, birth asphyxia, diarrhoea and malaria [1]. Almost 20% of
deaths in children aged under five years are considered
preventable by appropriate use of medicines [2].
Essential medicines are those that satisfy the priority healthcare
needs of the population. They should be available within the
context of functioning health systems at all times, in adequate
amounts and in the appropriate dosage forms [3,4]. However, very
few medicines exist in formulations developed specifically for
children, and lack of medicines for children has been a global
problem. To increase access to essential medicines for children, the
WHO launched the ‘‘Better Medicine for Children’’ initiative and
‘‘Make Medicines Child Size’’ campaign to raise awareness and
promote global action [5]. Three editions of the WHO Model List
of Essential Medicines for Children (EMLc) have already been
published between 2007 and 2011, which are intended for use by
children up to 12 years of age [6,7].
As in many other developing countries, few options exist in
China in terms of paediatric drugs and dosage forms, and the list
of essential medicines for children has yet to be introduced [8].
The 2009 National Essential Medicine List (NEML), which
includes 307 Western and Chinese medications, did not
sufficiently meet patients’ basic medical needs, especially for
children [9]. Although the newly released 2012 NEML [10]
included approximately 200 drugs that could be used for children
(including 70 formulations and specifications indicated for
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serious issue.
Gathering evidence on medicine prices and availability is the
first step in improving access to affordable treatment. In May
2003, WHO collaborated with Health Action International (HAI)
to develop a standardised method for surveying medicine prices,
availability, affordability and price components in selected sectors
in low- and middle-income countries [11]. Since then, access to
essential medicines has been studied widely using the WHO/HAI
methodology [12], but only a small number of studies [13–18] in
developing countries have been conducted to measure paediatric
medicine prices and availability and they did not cover China.
Given the paucity of data available on the availability and cost
to the patient of paediatric medicines in China, we conducted a
survey in the public and private sectors in six areas of Shaanxi
Province, Western China using the WHO/HAI methodology [19]
from November to December 2012, to measure the prices and
availability of 28 paediatric essential medicines. We also collected
price components data for five paediatric essential medicines
throughout the supply chain to obtain price mark-ups. To our
knowledge, this is the first such paediatric essential medicines
survey reported in China.
Methods
Ethics statement
The study was approved by the Ethics Committee of Xi’an
Jiaotong University Health Science Center. Shaanxi Provincial
Department of Health, and Shaanxi Food and Drug Administra-
tion approved the study before data collection. The participants
were informed of the aims of our study prior to participation. All
participants provided signed written informed consent forms.
Survey areas
For the price and availability survey, Xi’an, the capital city of
Shaanxi Province, was chosen as the major urban center, and an
additional five areas (Yulin, Baoji, Xianyang, Weinan, and
Ankang) within 1 day’s travel of Xi’an were randomly selected.
We investigated price components in two areas: Xi’an (the main
urban center) and Ankang (far from the urban center) to collect the
price mark-ups in the supply chain.
Selection of medicine outlets
In each survey area, we first selected the main public hospital,
which could be a tertiary hospital. An additional four public sector
medicine outlets, two secondary hospitals and two primary
hospitals were randomly chosen within 3 h travel of the main
hospital. The public sector sample therefore comprised five public
sector medicine outlets in each of the six survey areas, a total of 30.
The private sector sample also consisted of a total of 30 retail
pharmacies, one large-scale pharmacy, two medium-scale phar-
macies and two small-scale pharmacies in each area. The selected
pharmacies were those closest to each public medicine outlet. In
addition to the public and private sector outlets, back-up medicine
outlets nearest to, and representing the same level of care as the
first ones, were identified in case less than 50% of the medicines
were available at the first outlet.
We also recorded information on charges made for five
medicines starting at the dispensing point for public hospitals,
and tracking price components backwards along the supply chain
at different stages. The samples included manufacturers, public
hospitals, wholesalers and distributors.
Selection of survey medicines
A total of 28 medicines were surveyed, all of which were
registered in the country. Twenty-one of them were on the
WHO’s EMLc [20]. The other seven were selected based on the
local disease burden and needs (determined by a pilot survey), the
2009 NEML, Shaanxi Provincial Essential Medicine Supplemen-
tary List and the opinions of several groups of experts. Table 1 lists
all the survey medicines.
For each medicine, price and availability data were collected for
two products: the originator brand (OB) and the lowest price
generic (LPG) equivalent. The ‘‘originator brand’’ product is a
single-brand product marketed by the originator pharmaceutical
company. ‘‘Lowest price generic equivalents’’ are defined as the
same product sold under the generic name with the lowest unit
price at each medicine outlet at the time of data collection in the
survey. Twenty medicines were so old that it was not possible to
identify the originator brands, so data were only collected for the
generics.
For the price components survey, five of the 28 medicines
selected had high prices, and/or high use volumes and/or variable
pricing patterns. They covered four categories of drug formula-
tions (Table S1). Three of the five were included in the Shaanxi
Provincial Procurement List [21] and were purchased through
open tender and unified distribution channels.
Data Collection and Entry
Twelve well-trained data collectors visited medicine outlets and
collected data on medicine prices (procurement price and patient
price in public sector outlets, and patient price in private sector
outlets) and availability, using standardised price collection forms.
No specific permits were required for the described field studies.
Two trained personnel entered the data into the standardised
WHO/HAI Excel Workbook using a double-entry technique.
Four data collectors visited key informants along the drug
supply chain and collected price components data. Then, we
entered this information into the WHO/HAI Excel workbook.
Statistical Analysis
The availability of the investigated medicines was calculated as
the percentage (%) of medicine outlets in which the individual
medicine was found on the day of data collection. Mean
availability refers to the overall ‘‘basket’’ of medicines surveyed.
To facilitate comparisons with other countries, we used the
median price ratio (MPR) to express how much greater or less the
median local medicine price was than the international reference
price (IRP) in the Management Sciences for Health (MSH) 2011
Price Indicator Guide [22], e.g. an MPR of 2, would mean that
the local medicine price is twice the international reference price.
MSH international reference prices, which are generally offered
by not-for-profit suppliers to developing countries, are recom-
mended as the most useful standard. Generally, an MPR of one or
less indicates an efficient public sector procurement system and an
MPR of 1.5 and two is the cut-off point for patient price in the
public and private sector, respectively. Price ratios were not
calculated when the medicine was present in fewer than four
outlets.
Affordability was estimated to determine the number of days’
wages required to purchase the standardised treatment, using the
daily wage of the lowest-paid unskilled government worker. In
Shaanxi Province, this was RMB 29.5833 (USD 4.7061) [23]. If a
medicine treatment cost less than 1 day’s wages, we regarded its
affordability as good.
Data collected on the components of medicine prices were
analysed according to key stages in the supply chain. Prices were
Access to Paediatric Essential Medicines in China
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(MSP), wholesale procurement price, wholesale selling price,
public sector procurement price, final patient price and govern-
ment limited price. We calculated the mark-ups at every stage, and
the contribution of each stage to the final price.
Results
Medicine availability
The mean availabilities of OBs and LPGs were 10.8% and
27.3% in public hospitals and 11.9% and 20.6% in private
pharmacies. The availability of the selected medicines in both
sectors was low. For the 21 medicines listed on the EMLc, the
mean availability in the public hospitals was 7.5% for OBs and
27.9% for LPGs, and 3.6% for OBs and 25.2% for LPGs in
private pharmacies.
Table 1 shows the availability of individual medicines in both
the public and private sectors. Seven OBs were found in the public
sector, and seven in the private sector. For two medicines,
procaine penicillin and amoxicillin/clavulanic acid suspension,
neither their originator brands nor generic equivalents were found
in any of the survey outlets. Only seven LPGs in the public sector
and four in the private sector had .50% availability.
Medicine prices
Table 2 shows the median MPR of OBs and LPGs in the public
and private sectors. In the public sector, the procurement and
retail prices were 2.25 and 2.59 times the IRPs for three OBs, and
0.52 and 0.93 times the IRPs for 20 LPGs. The final patient prices
were 15.1% and 78.8% higher than procurement prices for three
OBs and 20 generic equivalents. The MPRs of three OBs—
albendazole (6.24), beclomethasone (2.59) salbutamol (1.75)—were
more than 1.5 times their IRPs. Six LPGs were also sold at more
than 1.5 times the reference price: fluconazole (5.31), oral
rehydration salts (2.22), amoxicillin/clavulanic acid (tablet)
(2.10), amoxicillin (1.82), albendazole (1.68) and salbutamol (1.34).
In the private sector, the final patient prices for OBs and LPGs
were 3.89 and 1.25 times their IRPs. The MPRs of the following
medicines were more than twice the IRPs: albendazole (6.00) for
Table 1. Availability of medicines in the public sectors and the private sectors.
Survey medicines
Public sector
availability (%)
Private sector
availability (%)
OBs LPGs OBs LPGs
Core list Amoxicillin (250 mg, capsule/tablet) — 58.3 — 78.3
Amoxicillin/ Clavulanic acid (125 mg+31.25 mg/5 ml, suspension) — 0 — 0
Azithromycin (250 mg, tablet) 3.3 33.3 1.7 60.0
Benzylpenicillin (1 million IU, injection) — 75.0 — 15.0
Calamine (100 ml, lotion) — 70.0 — 71.7
Carbamazepine (200 mg, tablet) 1.7 0 1.7 3.3
Cefazolin (1 g, injection) — 16.7 — 6.7
Ceftriaxone (250 mg, injection) 3.3 1.7 0 5.0
Chloramphenicol (250 mg, tablet) — 8.3 — 13.3
Chlorpheniramine (4 mg, tablet) — 68.3 — 75.0
Diazepam (5 mg/ml, injection) — 63.3 — 0
Fluconazole (50 mg,capsule) 5.0 16.7 1.7 30.0
Ibuprofen (200 mg, tablet) — 0 — 10.0
Isoniazid(100 mg, tablet) — 38.3 — 46.7
Morphine (10 mg, tablet) — 8.3 — 0
Oral rehydration solution (500 ml, oral solution) — 35.0 — 26.7
Paracetamol (500 mg, tablet) 0 5.0 3.3 13.3
Phenobarbital (30 mg, tablet) — 43.3 — 0
Phenytoin (50 mg, tablet) — 26.7 — 15.0
Procaine penicillin (600 mg, injection) — 0 — 0
Salbutamol (100 mcg/dose,inhaler) 31.7 16.7 13.3 33.3
Supplementary list Albendazole (200 mg, tablet) 31.7 6.7 70.0 6.7
Aminophylline (25 mg/ml, injection) — 21.7 — 6.7
Amoxicillin/ Clavulanic acid (250 mg+125 mg, tablet) — 6.7 — 10.0
Beclomethasone (50 mcg/ dose, inhaler) 10.0 0 3.3 0
Phenobarbital (100 mg/ml, injection) — 53.3 — 1.7
Vitamin A (25,000 IU, capsule) — 1.7 — 8.3
Vitamin B6 (50 mg/ml, injection) — 90.0 — 20.0
OBs: Originator brands; LPGs: Lowest-priced generics;
—: Not included in analysis.
doi:10.1371/journal.pone.0090365.t001
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oral rehydration salts (3.23) and aminophylline (2.45) for LPGs.
For those medicines found in both public and private sectors,
the median MPR for OBs and LPGs were 4.00 and 1.10 in the
public sector and 3.89 and 1.26 in the private sector. The final
patient price in the private sector was 2.8% lower than in the
public sector for OBs, and 14.5% higher for LPGs.
Affordability
The affordability of standard treatments for eight different
health conditions (16 medicines) is calculated. It includes three
OBs and 14 LPGs from public sector outlets and two OBs and 12
LPGs from private sector ones. The results showed that standard
treatments cost less than 1 day’s wages for both OBs (except for
beclomethasone, which cost 1.6 days’ wages) and LPGs in both
sectors. As a whole, the affordability was reasonable.
Price components
In China, no dispensing fee is applied in public hospitals. The
transport costs from manufacturers to wholesalers are included in
the procurement prices paid by wholesalers. The tax is generally
4%.
Tables 3 and 4 list the price components of five medicines in
Xi’an and Ankang. Final patient prices were lower than their
government-decided or guided prices. In Xi’an, the total mark-up
(from MSP to the final patient price) for salbutamol was 65.5%
and 185.3% for OB and generic. The total mark-up on amoxicillin
was 77.4%. The mark-ups for generic aminophylline, amoxicillin
and oral rehydration salts in public sector outlets were in the range
of 20–30%, with retail mark-ups all being around 15%. For two
other generic medicines, albendazole and salbutamol, the retail
mark-ups were zero (Table 3). In Ankang, for four generic
medicines, the cumulative mark-ups were in the range of 30–50%.
The retail mark-ups were around 15% for two generics
(amoxicillin and oral rehydration salts) and two originator brands
(albendazole and salbutamol) and zero for two other generics
(albendazole and aminophylline) (Table 4).
For five types of dosage forms in the survey, the cumulative
mark-ups varied, with the inhaler having the highest cumulative
mark-up in Xi’an and tablet form in Ankang. In the whole supply
chain, the MSP was the largest contributor (65.3%) to final patient
price in Xi’an, followed by the mark-up from wholesaler to
hospital (25.9%), and retail mark-up by hospitals (8.8%). Similarly
in Ankang, the relative contributions to the final patient price were
the MSP (76.0%), mark-up by wholesalers (15.2%), and mark-up
by hospitals (8.8%).
Discussion
No previous survey has been carried out to assess prices and
availability of paediatric essential medicines in China, although
some pricing and availability surveys [24–28] have been conduct-
ed for adult medicines using the validated methodology [19]. This
preliminary survey provides a valuable picture of the prices,
availability and affordability of essential medicines for children in a
reliable and standardised way in China.
The findings reported in this paper focus on the prices and
availability of 28 paediatric essential medicines in public hospitals
and retail pharmacies of six areas in Shaanxi Province. The results
showed that the availability of medicines was low in both sectors.
Public sector procurement and patient prices were high for OBs,
and both OBs and generics were expensive in private retail
pharmacies when compared with the IRPs.
In China, there is still no list of essential medicines for children,
and lack of access to paediatric essential medicine has caused
growing concern. Strengths and dosage forms suitable for children
were in short supply in the market. It is estimated that children
account for 20% of the total population in China, but paediatric
medicines accounted for only 2% of the total medicines available
[29]. In routine clinical treatment, doctors have become used to
reducing doses of adult medicines to deal with paediatric diseases.
The survey results, however, revealed that the situation might be
much more serious than previously thought. The availability of
existing OBs and their generic alternatives was lower than 30% in
both the public and private sectors, which could be attributed to
multiple factors: manufacturers’ lack of motivation to produce
because of low demand or small profit, less effective bidding and
procurement systems for paediatric medicines, hospitals’ prefer-
ences for higher-priced medicines, inappropriate drug selection
and prescription, and weak health and supply systems [30,31].
It was noted that no versions of amoxicillin/clavulanic acid
suspension and procaine penicillin were found in any of the survey
outlets. For the former, the originator brand was not stocked
because the manufacturer has removed all domestic amoxicillin/
clavulanic acid from the market because of contamination by
diisodecyl phthalate [32]. Neither the originator brand nor the
generic equivalent of the latter was procured in Shaanxi Province
[33]. However, when medicines are not available in hospitals or
retail pharmacies, patients will be given substitute medicines,
which may not be suitable for them.
By the end of 2011, the Shaanxi provincial government had
implemented ‘‘triple unification’’ (unified procurement, unified
price and unified distribution) and zero mark-up policies on
medicines in all the primary health facilities [34]. Results showed
that the retail prices for LPGs were lower in the public sector than
Table 2. Median MPRs for OBs and LPGs in the public and private sectors.
Product
type Public sector
Private
sector
No. of
medicines
Median procurement price
(MPR)
Median retail price
(MPR)
% difference retail to
procurement price
No. of
medicines
Median retail price
(MPR)
LPGs
All 20 0.52 0.93 78.8 19 1.25
EMLc 15 0.51 0.80 56.9 14 1.20
OBs 3 2.25 2.59 15.1 2 3.89
OBs: Originator brands; LPGs: Lowest-priced generics; MPR: Median price ratio.
EMLc: WHO Model List of Essential Medicines for Children.
doi:10.1371/journal.pone.0090365.t002
Access to Paediatric Essential Medicines in China
PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e90365T
a
b
l
e
3
.
P
r
i
c
e
c
o
m
p
o
n
e
n
t
s
f
o
r
p
a
e
d
i
a
t
r
i
c
m
e
d
i
c
i
n
e
s
i
n
X
i
’
a
n
.
M
e
d
i
c
i
n
e
M
S
P
(
Y
u
a
n
)
W
h
o
l
e
s
a
l
e
p
r
o
c
u
r
e
m
e
n
t
p
r
i
c
e
(
Y
u
a
n
)
W
h
o
l
e
s
a
l
e
s
e
l
l
i
n
g
p
r
i
c
e
(
Y
u
a
n
)
P
u
b
l
i
c
s
e
c
t
o
r
p
r
o
c
u
r
e
m
e
n
t
p
r
i
c
e
(
Y
u
a
n
)
F
i
n
a
l
p
a
t
i
e
n
t
p
r
i
c
e
(
Y
u
a
n
)
%
C
u
m
u
l
a
t
i
v
e
m
a
r
k
-
u
p
G
o
v
e
r
n
m
e
n
t
-
d
e
c
i
d
e
d
p
r
i
c
e
o
r
g
o
v
e
r
n
m
e
n
t
-
g
u
i
d
e
d
p
r
i
c
e
(
Y
u
a
n
)
L
P
G
s
A
l
b
e
n
d
a
z
o
l
e
2
0
0
m
g
T
a
b
l
e
t
2
.
3
0
2
.
3
0
2
.
7
0
2
.
8
0
2
.
8
0
2
1
.
7
6
.
4
0
A
m
i
n
o
p
h
y
l
l
i
n
e
2
5
m
g
/
m
l
I
n
j
e
c
t
i
o
n
0
.
5
4
0
.
5
4
0
.
6
0
0
.
6
0
0
.
6
9
2
7
.
8
0
.
8
4
A
m
o
x
i
c
i
l
l
i
n
2
5
0
m
g
C
a
p
s
u
l
e
6
.
2
0
6
.
2
0
6
.
8
0
9
.
6
0
1
1
.
0
0
7
7
.
4
1
1
.
5
0
O
r
a
l
r
e
h
y
d
r
a
t
i
o
n
5
0
0
m
l
O
r
a
l
s
o
l
u
t
i
o
n
0
.
3
5
0
.
3
5
0
.
3
6
0
.
3
8
0
.
4
4
2
5
.
7
7
.
9
0
S
a
l
b
u
t
a
m
o
l
1
0
0
0
m
c
g
/
d
o
s
e
i
n
h
a
l
e
r
1
2
.
9
0
1
2
.
9
0
1
3
.
6
5
3
6
.
8
0
3
6
.
8
0
1
8
5
.
3
5
2
.
9
0
O
B
s
S
a
l
b
u
t
a
m
o
l
1
0
0
0
m
c
g
/
d
o
s
e
i
n
h
a
l
e
r
1
4
.
2
0
1
4
.
2
0
1
4
.
5
0
2
0
.
3
9
2
3
.
5
0
6
5
.
5
2
3
.
8
0
O
B
s
:
O
r
i
g
i
n
a
t
o
r
b
r
a
n
d
s
;
L
P
G
s
:
L
o
w
e
s
t
-
p
r
i
c
e
d
g
e
n
e
r
i
c
s
;
M
S
P
:
m
a
n
u
f
a
c
t
u
r
e
r
’
s
s
e
l
l
i
n
g
p
r
i
c
e
;
Y
u
a
n
:
C
h
i
n
e
s
e
Y
u
a
n
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
9
0
3
6
5
.
t
0
0
3
T
a
b
l
e
4
.
P
r
i
c
e
c
o
m
p
o
n
e
n
t
s
f
o
r
p
a
e
d
i
a
t
r
i
c
m
e
d
i
c
i
n
e
s
i
n
A
n
k
a
n
g
.
M
e
d
i
c
i
n
e
M
S
P
(
Y
u
a
n
)
W
h
o
l
e
s
a
l
e
p
r
o
c
u
r
e
m
e
n
t
p
r
i
c
e
(
Y
u
a
n
)
W
h
o
l
e
s
a
l
e
s
e
l
l
i
n
g
p
r
i
c
e
(
Y
u
a
n
)
P
u
b
l
i
c
s
e
c
t
o
r
p
r
o
c
u
r
e
m
e
n
t
p
r
i
c
e
(
Y
u
a
n
)
F
i
n
a
l
p
a
t
i
e
n
t
p
r
i
c
e
(
Y
u
a
n
)
%
C
u
m
u
l
a
t
i
v
e
m
a
r
k
-
u
p
G
o
v
e
r
n
m
e
n
t
-
d
e
c
i
d
e
d
p
r
i
c
e
o
r
g
o
v
e
r
n
m
e
n
t
-
d
e
c
i
d
e
d
p
r
i
c
e
(
Y
u
a
n
)
L
P
G
s
A
l
b
e
n
d
a
z
o
l
e
2
0
0
m
g
T
a
b
l
e
t
1
.
4
0
1
.
4
0
2
.
1
0
2
.
1
0
2
.
1
0
5
0
.
0
2
.
5
0
A
m
i
n
o
p
h
y
l
l
i
n
e
2
5
m
g
/
m
l
I
n
j
e
c
t
i
o
n
0
.
4
0
0
.
4
0
0
.
5
3
0
.
5
3
0
.
5
3
3
2
.
5
0
.
8
4
A
m
o
x
i
c
i
l
l
i
n
2
5
0
m
g
C
a
p
s
u
l
e
7
.
8
0
7
.
8
0
8
.
8
0
9
.
7
0
1
1
.
2
0
4
3
.
6
1
1
.
5
0
O
r
a
l
r
e
h
y
d
r
a
t
i
o
n
5
0
0
m
l
O
r
a
l
s
o
l
u
t
i
o
n
3
2
.
6
9
3
2
.
6
9
3
5
.
8
0
3
7
.
8
0
4
3
.
5
0
3
3
.
1
4
4
.
0
0
O
B
s
A
l
b
e
n
d
a
z
o
l
e
2
0
0
m
g
T
a
b
l
e
t
9
.
0
7
9
.
0
7
8
.
9
8
9
.
0
0
1
0
.
4
0
1
4
.
7
1
1
.
0
0
S
a
l
b
u
t
a
m
o
l
1
0
0
0
m
c
g
/
d
o
s
e
i
n
h
a
l
e
r
1
9
.
2
1
9
.
2
2
0
.
3
9
2
0
.
3
9
2
3
.
4
0
2
1
.
9
2
3
.
8
0
O
B
s
:
O
r
i
g
i
n
a
t
o
r
b
r
a
n
d
s
;
L
P
G
s
:
L
o
w
e
s
t
-
p
r
i
c
e
d
g
e
n
e
r
i
c
s
;
M
S
P
:
m
a
n
u
f
a
c
t
u
r
e
r
’
s
s
e
l
l
i
n
g
p
r
i
c
e
;
Y
u
a
n
:
C
h
i
n
e
s
e
Y
u
a
n
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
9
0
3
6
5
.
t
0
0
4
Access to Paediatric Essential Medicines in China
PLOS ONE | www.plosone.org 5 March 2014 | Volume 9 | Issue 3 | e90365in the private sector, to some extent, indicating that the centralised
purchasing system plays an active role. However, the overall prices
for OBs were much higher than international reference prices and
therefore still need to be adjusted. Compared with OBs, the
relatively low retail prices for LPGs are probably due to the fierce
market competition in China [35]. The results were consistent
with a number of pricing and availability surveys [24–27] that
have been conducted for adult medicines in China.
In this study, we considered affordability of medicines for eight
different paediatric health conditions, mostly focusing on acute
diseases. This is consistent with actual treatments for children.
These standard treatments cost less than 1 day’s wages, because
the treatment duration for acute conditions is shorter than for
chronic diseases. These findings are different from those of other
studies [36–38] into affordability of adult medicines, which showed
that acute medicines were unaffordable for many people,
particularly in private sector outlets. However, treatment for
asthma with beclomethasone (costing 1.6 days’ wages) was
unaffordable in the public sector. Beclomethasone is used in the
ongoing treatment of a chronic condition, making it even less
affordable.
Generally, high mark-ups and profit margins were noted in the
public sector, while the final patient prices did not exceed the
ceiling prices set by the government. However, we recommend
urgently that the government should substantially improve public
drug procurement and price management, making the procure-
ment system more efficient and the pricing system more scientific,
rational and transparent [39].
The present study has several limitations. First, although
alternate strengths of the same medicine existed in the survey
outlets, they were not recorded in the pre-determined medicine
price data collection form. As a result, the medicine availability
estimates in this survey may be biased. Second, availability data
only apply to the day of data collection and may not reflect
average availability over time. Third, limited price data were
obtained, because of the low availability of the medicines surveyed.
Only two and three originator brand medicines in private and
public sectors, respectively, had the required four prices to enable
calculation of the MPRs. Low availability of drugs in both sectors
therefore makes the median MPR less robust. Finally, this study
analysed price components of paediatric essential medicines in
China using the standardised WHO/HAI methodology. However,
only five medicines were included in the analysis with limited price
data collected along the supply chain, because of confidentiality
and sensitivity.
Conclusions
In both the public and private sectors, generic paediatric
medicines had better availability than originator brands, but
availability was still very low. The affordability was reasonable,
although high mark-ups existed along the supply chain for all the
paediatric essential medicines surveyed. We recommend that
relevant measures should be taken to enable children to obtain
sufficient medicines and effective treatment at affordable prices.
The government should adjust the prices of originator brands and
lowest-priced generics and improve the efficiency of centralised
medicine purchasing systems.
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